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The efficacy of hormonal therapies for advanced estrogen receptor-
positive breast cancers is limited by the nearly inevitable de-
velopment of acquired resistance. Efforts to block the emergence
of resistance have met with limited success, largely because the
mechanisms underlying it are so varied and complex. Here, we
investigate a new strategy aimed at the very processes by which
cancers evolve resistance. From yeast to vertebrates, heat shock
protein 90 (HSP90) plays a unique role among molecular chaper-
ones by promoting the evolution of heritable new traits. It does so
by regulating the folding of a diverse portfolio of metastable cli-
ent proteins, many of which mediate adaptive responses that al-
low organisms to adapt and thrive in the face of diverse challenges,
including those posed by drugs. Guided by our previous work in
pathogenic fungi, in which very modest HSP90 inhibition impairs
resistance to mechanistically diverse antifungals, we examined the
effect of similarly modest HSP90 inhibition on the emergence of
resistance to antiestrogens in breast cancer models. Even though
this degree of inhibition fell below the threshold for proteotoxic
activation of the heat-shock response and had no overt anticancer
activity on its own, it dramatically impaired the emergence of re-
sistance to hormone antagonists both in cell culture and in mice. Our
findings strongly support the clinical testing of combined hormone
antagonist-low-level HSP90 inhibitor regimens in the treatment of
metastatic estrogen receptor-positive breast cancer. At a broader
level, they also provide promising proof of principle for a generaliz-
able strategy to combat the pervasive problem of rapidly emerging
resistance to molecularly targeted therapeutics.
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Drastically limiting the efficacy of targeted therapeutics, theemergence of drug resistance in advanced cancers re-
mains nearly inevitable. From yeast to vertebrates, the molecular
chaperone heat shock protein 90 (HSP90) allows organisms to
adapt and thrive in the face of diverse challenges, including
those posed by drugs and environmental stressors (1, 2). It does so
by regulating the folding of a highly diverse portfolio of metastable
client proteins, many mediating adaptive responses (3, 4).
However, this role for HSP90 in adaptation is greatly magni-
fied by its ability to promote the evolution of heritable new traits.
To buffer the proteome against unexpected environmental
challenges, HSP90 is present in large excess under normal cir-
cumstances. This buffering capacity allows it to modulate the
manifestation of preexisting and newly acquired genetic variation
within heterogeneous populations of cells, and even whole
organisms, thereby dramatically expanding the range of pheno-
types on which selection can act (1, 2, 5–7). As a dramatic,
therapeutically relevant example, we have shown that this HSP90
buffer enables fungal pathogens spanning ∼1 billion years of
evolution to evolve and maintain resistance to every major an-
tifungal in general use (8, 9). Now we ask whether HSP90 might
serve a similar role in buffering the molecular and genetic het-
erogeneity present in human tumors and whether low-level in-
hibition might limit the emergence of drug resistance.
At this time, HSP90 inhibitors are being developed as anti-
cancer therapeutics, with a much simpler rationale: Many pro-
teins that drive the malignant phenotype depend on HSP90’s
protein-folding activities for their function (10–13). The hope is
that the “addiction” of cancer cells to such client proteins will
create a therapeutic window: Substantial HSP90 inhibition would
block the maturation of oncogenic “drivers” without harming
normal cells. The rub is that an important normal function of
HSP90 is to bind the stress-responsive transcription factor heat-
shock factor 1 (HSF1) and repress its activities. High levels of
HSP90 inhibition, therefore, activate HSF1, which has recently
emerged as a powerful enabler of malignancy in both cancer cells
and the stromal cells that support them (14, 15).
Ironically, the biomarker that has been most broadly used in
clinical trials to verify that high, oncoprotein-depleting levels of
HSP90 inhibition have been achieved is the increased expression
of HSP70. Because HSP70 expression is regulated by HSF1, it
serves as a surrogate marker for the activation of this factor (16,
17). Thus, in practice, at the levels of HSP90 inhibition currently
sought in the clinic, the very real benefits that might be achieved
through the differential vulnerability of cancer cells are likely to
be attenuated by the activation of HSF1.
Here we ask whether HSP90 could be effective against cancers
in an entirely different manner. Our previous work has demon-
strated an ancient, highly conserved function for HSP90 in
supporting the evolution of new traits in diverse organisms.
Might the emergence of resistance to an anticancer therapeutic
in the heterogeneous population of cells that make up a cancer
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Although hormonal therapies for estrogen receptor-positive
(ER+) breast cancer make up the earliest, and arguably most
effective, “molecularly targeted” anticancer drugs, continued
progress in controlling metastatic disease has been slow. Het-
erogeneity and the complexity of signaling in advanced can-
cers have frustrated efforts to prevent the rapid evolution of
resistance to hormonal therapies, as well as kinase inhibitors
and other agents. On the basis of earlier work defining the role
of heat shock protein 90 (HSP90) in other evolutionary processes,
we tested whether low-level HSP90 inhibition would limit the
evolution of hormone resistance in breast cancer models. Results
in culture and in mice provide support for a readily implemented
strategy by which the heterogeneity and evolvability of meta-
static ER+ breast tumors, and perhaps other advanced cancers,
might be controlled.
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be prevented by modest, non-HSF1-activating levels of HSP90
inhibition (16–18)? As a specific test of this hypothesis, we ex-
amined whether levels of HSP90 inhibition that are much lower
than those commonly used could restrict the ability of tumors to
evolve resistance to hormonal therapy in models of estrogen re-
ceptor-positive (ER+) breast cancer. Almost all women with ad-
vanced ER+ breast cancer inexorably progress through multiple
forms of hormonal therapy, to ultimately die of multidrug-resistant
disease (18, 19). If low levels of HSP90 inhibition have the power to
stop this evolutionary process, it could both address an urgent un-
met need and provide compelling support for the broader thera-
peutic potential of targeting evolutionary mechanisms (20–22).
Results
Modest HSP90 Inhibition Limits Tam Resistance in Culture. We first
defined threshold exposure conditions for an HSP90 inhibitor
that alone would exert no direct effect on growth of the ER+
breast cancer cell line MCF-7. This line was established from the
pleural effusion of a patient with metastatic disease and displays
considerable clonal heterogeneity at the genetic and phenotypic
levels (23). As the HSP90 inhibitor, we chose ganetespib, a syn-
thetic second-generation agent in late-stage clinical development
that has markedly improved pharmacology over earlier natural
product-derived compounds (24, 25). We found that concen-
trations of ganetespib ≤10 nM met the specified criterion for
lack of growth inhibition (Fig. 1A). We then examined clonogenic
outgrowth of cells cultured continuously for 1 mo in tamoxifen
(4-hydroxytamoxifen, Tam) a widely used antiestrogen. Low nano-
molar concentrations of ganetespib, which alone did not alter cell
accumulation, markedly reduced the appearance of Tam-resistant
clones (Fig. 1B and Fig. S1A). This effect was not restricted to
HSP90 inhibition by ganetespib because an alternate chemotype,
the prototypical natural product HSP90 inhibitor geldanamycin,
also dramatically suppressed the emergence of Tam-resistant
clones at concentrations that did not alter cell accumulation on
their own (Fig. S1B).
The powerful effect of modest HSP90 inhibition was con-
firmed genetically, using low-level, stable knockdown of either
HSP90α or HSP90β in MCF-7 cells (Fig. S2 A and B). Knock-
down of either isoform had no general effect on growth in the
absence of Tam, but it dramatically reduced the emergence of
Tam-resistant clones during long-term culture.
To determine whether this modest level of knockdown did
actually affect the HSP90 buffer, we examined the maturation of
two well-established HSP90 client proteins, the receptor tyrosine
kinases insulin-like growth factor 1 receptor (IGF-1R) and human
epidermal growth factor receptor 2 (HER2). Under basal con-
ditions, flow cytometry demonstrated no differences in receptor
levels. However, the hairpins did reduce available HSP90 capacity
because on challenge with geldanamycin, surface expression of
these kinases was more severely affected in cells carrying the
knockdown hairpins (Fig. S2C).
One explanation for the effect of HSP90 inhibitor on the emer-
gence of Tam resistance is classical drug–drug synergy. This
common effect increases anticancer activity by altering the dose–
response relationship for one agent in the presence of another (26).
To test for pharmacologic synergy, we measured the concentration-
dependent inhibition of MCF-7 cell accumulation after 5 d in var-
ious concentrations of ganetespib and the same saturating concen-
tration of Tam (1 μM) used in clonogenic assays. Across a broad
range of ganetespib concentrations, we saw no synergistic in-
teraction with Tam in short-term growth assays (Fig. 1A). Specifi-
cally, at the concentrations used in our clonogenic assays, ganetespib
with Tam had no greater effect than Tam alone (Fig. 1A, inset).
Combination Treatment Limits Escape from Cell Cycle Arrest. We
treated MCF-7 cells under the same conditions used for clono-
genic assays, but for only 10 d. Vehicle control and ganetespib-
treated cultures became densely confluent. In cultures exposed
to Tam alone, emergent foci of resistant cells had begun to ap-
pear on a background monolayer of growth-inhibited cells. In
cultures treated with a combination of Tam and ganetespib, the
monolayer was still largely intact, but no such foci were apparent
(Fig. 2A). We then measured relative mRNA levels genome-
wide. In contrast to typical high-level HSP90 inhibition, the low
concentration of ganetespib used in our experiments induced
changes in the expression of only a small number of genes. Im-
portantly, stress response and heat-shock protein genes were
notably absent, indicating that HSF1 had not been activated (Fig.
2B, Fig. S3A, and Dataset S1). Likewise, low-level HSP90 in-
hibition did not appear to directly impair the transcriptional
activating activity of the ER, a well-recognized client protein.
Ganetespib-only treatment had no consistent effect on the ex-
pression of genes that had consensus estrogen response elements
within 2 kb of their transcriptional start sites and that were down-
regulated ≥twofold by treatment with Tam alone (Fig. S3B).
As expected from its known cytostatic activity, with Tam
treatment, changes in cell cycle-associated genes were seen.
Combination Tam and ganetespib treatment, however, greatly
accentuated the drop in cell cycle-associated gene expression and
expanded the number of genes with reduced expression in the
categories of “cell cycle” and “DNA replication” (Fig. 2B).
Strikingly, combination treatment also augmented the down-
regulation of genes with regulatory motifs bound by E2F family
transcription factors. E2F regulates progression through several
points in the cell cycle, especially the G1-S transition, and has
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Fig. 1. Very modest pharmacologic inhibition of HSP90 function limits the
emergence of Tam resistance in cell culture. (A) Dose–response testing. MCF-7
cells were cultured for 5 d with ganetespib (Gan), Tam, or a combination of
Tam (1 μM) plus serial dilutions of Gan. Concentration-dependent inhibition
of relative MCF-7 cell mass was measured by standard sulforhodamine B
protein assay. (B) Clonogenic assays. MCF-7 cells were cultured continuously
in the presence of the indicated concentrations of the HSP90 inhibitor,
ganetespib, with or without concurrent Tam (1 μM). After 1 mo, cells were
fixed with cold methanol, and the macroscopic outgrowth of resistant col-
onies was visualized by staining with Diff-Quik. Photomicrographs of rep-
resentative wells are provided in Fig. S1A.
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been implicated in resistance to hormone deprivation (27, 28). In-
creased expression of genes associated with both stress responses
and apoptosis was another unique feature of the transcriptional
profile induced by combination treatment (Fig. 2B). In agreement
with our transcriptional profiling, low-dose ganetespib alone did not
affect the levels of several cell cycle progression-associated proteins,
and the effect of Tam alone was mixed (Fig. 2C). When ganetespib
was combined with Tam, however, cyclin-dependent kinase 4
(CDK4), Cyclin D1, and myelocytomatosis (MYC) levels were all
strongly and uniformly reduced, indicating a more complete, ho-
mogeneous treatment response.
Effect of Modest HSP90 Inhibition on Hormone Resistance Is Not
Limited to Tam. To test the generality of our findings, we next
asked whether low-level HSP90 inhibition would also block the
emergence of resistance to fulvestrant (Fulv), a mechanistically
distinct hormone antagonist. In contrast to Tam, which drives
association of the ER with DNA in repressive transcriptional
complexes, the pure antiestrogen Fulv induces proteasome-
mediated degradation of the ER (29). In clonogenic assays,
combination ganetespib–Fulv treatment profoundly inhibited the
emergence of Fulv resistance in MCF-7 cells. Again, this oc-
curred at concentrations of ganetespib that alone had no effect
on cell cycle progression (Fig. 2 B and C) or cell accumulation
over the course of month-long assays (Fig. 3A). Furthermore, the
effect was not restricted to MCF-7 cells. Ganetespib–Fulv com-
bination treatment was also effective against the established ER+
lines T47D (Fig. 3A) and ZRF-75.1 (Fig. S4). Demonstrating the
specificity of these effects, combination treatment had no effect
on the ER-negative breast cancer line HCC-38.
Because expression profiling had revealed a striking down-
regulation of genes controlled by the E2F family of transcription
factors, we engineered our breast cancer lines to express lucif-
erase under the control of E2F response elements. After 5 d,
before cytological changes were evident, Fulv reduced E2F re-
porter activity in the ER+ cell lines (Fig. 3B). As expected for an
ER-negative line, Fulv did not affect reporter activity in HCC-38
cells, either alone or in combination with ganetespib. In ER+
cells, however, low-level ganetespib induced a more profound
decline in reporter activity than was achievable by Fulv alone.
Impairment of Multiple Bypass Mechanisms Helps Limit Resistance.
To begin investigating mechanisms by which the addition of low-
level HSP90 inhibition could prevent the emergence of re-
sistance, we assayed MCF-7 lysates for the levels of key proteins
in pathways previously implicated in the development of hor-
mone resistance. As expected, Tam mildly increased ER levels
because it does not destabilize the ER but, instead, prolongs its
association with DNA in repressive transcriptional complexes
(29) (Fig. S5A). In contrast, Fulv reduced ER levels, as expected.
Low-dose ganetespib did not reduce ER levels but did block the
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Fig. 2. More uniform and profound cell cycle arrest is caused by exposure to
a combination of Tam and low-dose HSP90 inhibitor than to either agent
alone. (A) Photomicrographs of Diff-Quick-stained MCF-7 cell monolayers after
10 d in culture with Vehicle (DMSO 0.1% vol/vol and ethanol 0.01% vol/vol),
Tam 1 μM, Gan 10 nM, or Gan +Tam (G+T, 1 μM + 10 nM). The white arrow
indicates outgrowth of a Tam-resistant focus. All images were obtained at the
same magnification. (Scale bar, 50 μm.) (B) Relative mRNA expression levels and
gene set enrichment analysis for cells treated as in A. (C) Immunoblotting to
assess levels of the indicated proliferation-associated proteins in lysates pre-
pared from cultures treated as in A. Tubulin is used as a loading control.
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Fig. 3. Very modest pharmacologic inhibition of HSP90 limits the emer-
gence of Fulv resistance in ER+ breast cancer cells. (A, Upper) Macroscopic
images of Diff-Quick-stained wells after culture for 1 mo in the indicated
concentrations of ganetespib, with or without concomitant Fulv (1 μM).
(Inset) Relative cell number per well, expressed as percentage vehicle con-
trol, was monitored using Sytox green fluorescence as a measure of DNA
content. MCF-7 and T47D are estrogen-responsive human breast cancer cell
lines; HCC-38 is a triple-negative, estrogen-independent cell line. (Lower)
Photomicrographs obtained from the same wells. All images were acquired
at the same magnification. (Scale bar, 50 μm.) (B) Combined treatment
enhances the inhibition of E2F transcriptional activating activity. The in-
dicated cell lines were stably transduced with an E2F-regulated luciferase
reporter construct and treated as indicated for 10 d: vehicle (0.1% DMSO +
0.01% ethanol), ganetespib (10 nM), Fulv (1 μM), and G+F (ganetespib 10 nM +
Fulv 1 μM). Reporter activity is normalized to the protein concentration in
each lysate. Mean of quadruplicate determinations is presented. Error bars,
SEM; *P < 10−2, **P < 10−3 (Student t test, two-sided, unpaired).
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increase induced by Tam. More striking, it also enhanced ER
depletion by Fulv. We also looked at compensatory up-regula-
tion of receptor tyrosine kinase signaling. Such up-regulation,
especially of epidermal growth factor receptor (EGFR) family
signaling, is one of the major mechanisms contributing to Fulv
resistance in patients with breast cancer (30, 31). As expected,
exposure of MCF7 cells to Fulv for 10 d increased the levels of
family members EGFR and HER2 (Fig. S5B). Treatment with
low-dose ganetespib alone did not deplete total cellular levels of
these kinases, as measured by immunoblot. Looking more closely
at cell surface HER2 levels by flow cytometry, we did find
a modest decline, suggesting that some impairment in the mat-
uration of this very sensitive HSP90 client is caused by reducing
HSP90 buffering capacity with low-dose ganetespib (Fig. S6).
Most important, however, cotreatment with ganetespib and Fulv
completely blocked the adaptive increase in EGFR and HER2
induced by Fulv (Fig. S5B). It also drove near-complete loss of
phosphotyrosine signal in the SDS/PAGEmigration position of all
four EGFR family kinase members (175–185 kDa). Probing
downstream of receptor signaling, we also found that similar to
Tam (Fig. 2C), Fulv combination with ganetespib increased the
depletion of diverse proteins associated with cell cycle progression
and proliferation (Fig. S5C).
Combination Treatment Inhibits the Emergence of Resistance in
Xenografts. Can low-level, noncytotoxic HSP90 inhibition limit
the emergence of hormone resistance in vivo? To address this
question, we used a xenograft model in which MCF-7 tumors
were established in estrogen-supplemented mice. We defined
a low-dose, twice-weekly schedule for the water-soluble gane-
tespib prodrug (STA-1474) that demonstrated no antitumor ac-
tivity on its own (Fig. 4A). Tamoxifen was administered using
a standard dose and schedule that slowed tumor progression, but
consistent with previous reports (30), it failed to provide durable
control in our model (Fig. 4A). However, when tamoxifen was
combined with low-dose STA-1474, which had no effect on its
own, we saw a marked, persistent improvement in tumor control.
This improvement in efficacy appeared to arise from a decline in
the emergence of resistance to tamoxifen monotherapy. By day 39
of the experiment, considerable heterogeneity in tumor burden had
developed in the tamoxifen-alone treatment group, but not the
combination group (Fig. 4B). The marked ability of the combination
treatment to reduce heterogeneity in treatment response translated
into a dramatic improvement in event-free survival (Fig. 4C).
The different outcomes for these treatment regimens were
reflected at the histologic level in tumors analyzed by H&E
staining (Fig. 4D). Tumors from vehicle-treated mice showed
relatively homogenous sheets of poorly differentiated adenocarci-
noma sparingly infiltrated with stromal and connective tissue ele-
ments. The tumors of the STA-1474 group were similar. In contrast,
tamoxifen-treated tumors showed small nests of tumor cells within
dense bands of infiltrating fibrous stroma. Even more strikingly,
combination-treated tumors showed extensive vacuolization in ad-
dition to the fibrotic changes seen in tamoxifen-treated tumors.
At the molecular level, the up-regulation of ER and HER2
levels induced by tamoxifen alone was blocked by combination
treatment with tamoxifen and low-dose ganetespib (Fig. S7 A
and B), consistent with effects seen in cell culture (Fig. S5 A and
B). In addition, tumors exposed to the combination of tamoxifen
and STA-1474 showed increased differentiation, as monitored by
membranous expression of the epithelial marker MUC1, which is
typically lost during malignant progression (32) (Fig. S8). In
MCF-7 xenografts, we found only scant cytoplasmic staining
in vehicle-treated animals. In contrast, MUC1 expression was
strongly up-regulated in tumors treated with tamoxifen/STA-
1474 and exhibited a membranous staining pattern reminiscent
of normal breast tissue (Fig. 4E). Along with evidence of cyto-
differentiation, combination treatment induced profound cell
cycle arrest in xenografts as well. The mitotic index of tumors
was uniformly low across all samples in the combination treat-
ment group (Fig. S7C). Cyclin D1 and phospho-retinoblastoma
protein (RB) were also reduced to a much greater extent than
was achieved by tamoxifen alone (Fig. 4E and Fig. S7D). As in
cell culture, more profound and homogeneous cell cycle with-
drawal was a hallmark of combination treatment.
Discussion
Previous studies across a wide spectrum of organisms have
established the unique character of the HSP90 protein-folding
buffer and how it facilitates the evolution of diverse new bio-
logical phenotypes, including drug resistance (1, 2, 5, 6, 9). Now
we show that targeting this ancient, highly conserved role of
HSP90 in supporting the evolution of new traits could provide
a much needed approach to limiting the evolution of hormone
resistance in ER+ breast cancer, a setting in which no curative
treatment options exist for advanced disease.
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Fig. 4. Low-level HSP90 inhibition, having no effect on its own, limits the
emergence of Tam resistance in mice and prolongs survival. (A) Antitumor
activity of single-agent and combination treatments in estrogen-supple-
mented mice bearing MCF-7 xenografts. Mean tumor volume (eight mice
per treatment group) is plotted. Bars, SEM. P value for the difference between
Tamoxifen and Tam + STA groups was determined by two-way repeated-
measures ANOVA. (B) Heterogeneity in tumor size within treatment groups
at day 39 after cell implantation is reduced by combination treatment.
Horizontal bars indicate median with interquartile range. P values were
determined by Student t test (two-sided, unpaired). ns, not significant. (C)
Combination treatment markedly prolongs event-free survival. Kaplan-
Meier analysis is presented, using death or euthanasia for body condition
score <2 or excess tumor volume (>1,500 mm3) as event endpoints. The P
values for differences from vehicle control were determined by Log-rank test.
(D) H&E staining reveals a marked effect of combination treatment on tumor
histology. Images were acquired at the same magnification. (Scale bar, 50 μm.)
(E) Combination treatment increases expression of membranous MUC1 stain-
ing, as monitored by immunohistochemistry (IHC). (Scale bar, 50 μm.) (F)
Combination treatment enhances depletion of Cyclin D1 levels detected by
IHC. (Scale bar, 50 μm.)
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Indeed, our data suggest that the current paradigm driving
the clinical development of HSP90 inhibitors as broad-spectrum
inhibitors of drug-resistant kinases is missing the greater clinical
potential of these agents. Bolus dosing of current HSP90 inhib-
itors is well-tolerated and does transiently destabilize multiple
oncogenic kinases, but systemic toxicity increases prohibitively as
the duration of high-level HSP90 inhibition is extended. Un-
fortunately, HSP90 client levels return to baseline within a few
days of drug administration, and high-level inhibition comes at
the cost of stimulating tumor-supportive HSF1 activation. In
contrast, we now report that very modest, sustained inhibition of
HSP90, at well-tolerated levels that do not deplete clients on
their own or activate HSF1, reduces heterogeneity in the re-
sponse of tumors to antiestrogens and prolongs the duration of
disease control by these agents. Focusing on these striking effects
of low-level, noncytotoxic HSP90 inhibition, the current study
provides a new perspective, one very different from the many
previous reports describing interesting activity for high-level
HSP90 inhibition against recurrent drug-resistant cancers (33–
36) or synergistic interaction with other chemotherapeutics to
increase their activity (37–39). From a translational perspective,
the recent development of orally bioavailable HSP90 inhibitors
should make sustained, low-level inhibitor exposure feasible
in patients. The identification of genes that are modulated by
ganetespib at lower concentrations than classical heat-shock
protein genes suggests an approach to therapeutic monitoring in
patients that targets dose levels that modulate these sensitive
genes while sparing induction of heat-shock protein genes, the
antithesis of current dosing strategies that have sought to maxi-
mize heat-shock induction as a pharmacodynamic endpoint.
Even at initial diagnosis, tremendous heterogeneity is seen in
cellular levels of the ER protein, both within an individual breast
tumor and between different tumors. Any level of ER expression
(i.e., >1% of cells) is considered “ER positive,” although
patients with tumors demonstrating 1–10% staining appear to
derive less benefit from endocrine therapy than those with 10%
or higher staining. Such heterogeneity is also a feature of our
MCF-7 xenograft model, in which cells within vehicle control
tumors were seen with little or no ER staining, despite the ma-
jority being positive (Fig. S7A, Veh). For reasons that are not
clear, however, hormonal therapy does not usually drive the
outgrowth of ER-negative cells either in patients (22) or in our
xenograft model (Fig. S7A, Tam and T+S). For the vast majority
of patients with ER+ tumors, receptor expression is preserved
and alternate, ligand-independent modes of activation involving
oncogenic switching or constitutively activating mutation are
seen. Often, heterogeneity in resistance mechanisms can be seen
even within the tumor burden of a single patient, as dramatically
illustrated by a recent study of ex vivo cultured circulating tumor
cells isolated from patients with advanced ER+ breast cancer
(40). Importantly, in this study, cells with clinically acquired re-
sistance to multiple types of endocrine therapy demonstrated
increased sensitivity to low-level HSP90 inhibition, suggested by
the authors to be a result of the extreme dependence of their
mutant ER on HSP90 for stability.
With so many avenues to resistance available, perhaps it is not
surprising that clinical trials in patients with metastatic breast
cancer combining endocrine therapy with inhibitors that selec-
tively target individual bypass proteins have been disappointing
(41, 42). So how is low-level HSP90 inhibition different? Our
data show that it is not short-term pharmacological synergy.
Rather, combination therapy limits tumor adaptation and escape
from the cytostatic effects of disrupting ER function. As evi-
denced by such endpoints as CDK4 levels, RB phosphorylation,
and E2F-regulated gene expression, a far more profound block
to cell cycle progression is enforced by extended combinatorial
treatment than can be achieved with either low-level HSP90
inhibition or hormone antagonists alone (27, 28). Viewed from
an evolutionary perspective, this loss of replicative potential is
likely to be a major factor in limiting the accumulation of de
novo mutations or the emergence of preexisting resistant clones
within a heterogeneous tumor cell population (20).
Intriguing clinical support for this hypothesis comes from
a recent report describing significant clinical benefit on com-
bining the cyclin-dependent kinase inhibitor PD-0332991 with an
estrogen-depleting aromatase inhibitor (43). Because prolonged
exposure to the combination of Fulv or tamoxifen with ganetespib
is associated with the impairment of multiple bypass pathways, as
well as impairment of ER function itself, the cell cycle block we
demonstrate for combination of these antagonists with HSP90
inhibitor could provide even more durable disease control than
a CDK + aromatase inhibitor combination.
Since the initial discovery of natural products that inhibit
HSP90 over 2 decades ago, tremendous progress has been made
in developing potent and specific drugs with which to target this
chaperone. The most efficacious way to use these compounds in
cancer therapy, however, remains to be defined. With their po-
tential to act as inhibitors of the intrinsic ability of tumors to
evolve, we now suggest they could provide a much-needed ap-
proach to controlling the emergence of drug resistance, which is
perhaps the greatest current barrier to the development of
curative therapies.
Materials and Methods
Cell Lines and Reagents. The human breast cancer cell lines MCF-7, T-47D, ZRF-
75.1, and HCC-38 were obtained from the American Type Culture Collection,
cultured under standard conditions, and confirmed to be negative for my-
coplasma contamination by monthly surveillance testing. Sources for all
chemical reagents and methods for their formulation are detailed in SI
Materials and Methods.
Clonogenic Drug-Resistance Assays. Breast cancer cells were plated in 6-well
format (105 cells per well) or 15-cm dish format (2 × 106 cells per dish) and
allowed to adhere overnight. Compounds were added the following day,
and cultures were refed with fresh drug-containing medium twice weekly
for 4 wk. Wells were then fixed in cold methanol and stained with toluidine
blue (0.1%) or Diff-Quik. To measure their relative cell content, fixed wells
were incubated with the fluorescent DNA-binding dye Sytox Green (Invi-
trogen, 500 nM in PBS for 30 min) before Diff-Quik staining and relative
fluorescence intensity was determined, using a multiwell plate reader
(Safire2; Tecan).
Gene Knockdown and Flow Cytometry. Lentiviral pLKO.1-puro shRNA con-
structs were obtained from the Broad Institute RNAi platform. The specific
sequence information is provided in SI Materials and Methods. Viral super-
natants were prepared by standard methods and used to infect MCF-7 cells,
followed by selection in puromycin (InvivoGen) for 10 d. Stably transduced
cells were subcultured for 1 mo before measurement of HSP90 levels by im-
munoblotting, using antibodies directed against HSP90α (SPA-771), HSP90β
(SPA-843), and total HSP90 (SPA-835, all HSP90 antibodies from StressGen/
Enzo). Flow cytometric measurement of relative l HER-2 and IGF1 receptor levels
on the surface of stably transduced MCF-7 cells was performed, using standard
methods, as described in SI Materials and Methods.
Proliferation and Survival Assays. The measurement of relative viable cell
numbers was performed in 96-well microplate format, using the fluorescent
detection (Ex/Em: 540/590) of resazurin dye reduction as an endpoint. To
measure cell mass independent of potential metabolic changes induced by
drug exposure, plates were stained with 0.4% sulforhodamine B solution (In
Vitro Toxicology Assay Kit; Sigma), per the manufacturer’s instructions.
mRNA Expression Profiling and Analysis. MCF-7 cells were treated for 10 d,
followed by RNA extraction, using an RNeasy kit per the manufacturer’s
recommendation (Qiagen). Genome-wide expression analysis was per-
formed using Agilent 8 × 60K multiplex arrays. Data are provided in
Dataset S1 and were processed as previously described (14). Gene set en-
richment analysis of differentially expressed genes after drug treatment
was performed using the Molecular Signatures Database (MsigDB) Web
site, release version 3.84 (44).
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E2F Reporter Assays. Breast cancer cells were stably transduced with a com-
mercial lentiviral construct encoding firefly luciferase under control of
a minimal CMV promoter and tandem repeats of an E2F-response element
(Cignal Lenti E2F Reporter, SABiosciences). After puromycin selection,
transduced cells were plated in 24-well format. Compounds were added the
following day, and cultures were refed with fresh drug-containing medium
every 3 d. After 9 d of treatment, wells were rinsed with PBS and cells were
lysed in nondenaturing buffer. Lysates were assayed for luciferase activity
using Steady-Glo reagent (Promega) and protein concentration, determined
by bicinchoninic acid assay (BCA, Pierce/Thermo).
Immunohistochemical Staining. MCF-7 tumor xenografts were processed as
formalin-fixed, paraffin-embedded tissue blocks. Antigen retrieval was per-
formed on deparaffinized sections, using a pressure cooker with Dako citrate
buffer (pH 6.0) at122 ± 2 °C, 15 ± 5 psi for 45 s. Sections were then incubated
with primary antibodies (see SI Materials and Methods for details). Detection
was achieved by incubation for 30 min at room tempwith polymer anti-rabbit-
HRP (DakoCytomation) and signal developed in 3,3’-Diaminobenzidene for
3 min, followed by counterstaining with Gill hematoxylin.
Immunoblotting.Whole-cell protein extracts were prepared in nondenaturing
lysis buffer and immunoblotted to measure the relative levels of specific
proteins, using standard methods, as detailed in SI Materials and Methods.
Xenograft Tumor Model. Female nonobese diabetic-SCID mice were estrogen-
supplemented by s.c. implantation of slow-release 17β-estradiol pellets (0.72
mg/90-d release; Innovative Research of America) 1 d before MCF-7 tumor cell
injection into the mammary fat pad (5 × 106 MCF-7 cells suspended in a 1:1
PBS:Matrigel solution). Details for the measurement of tumor volume and
treatment protocol with tamoxifen citrate and HSP90 inhibitor are provided in
SI Materials and Methods. Treatments were continued for the entire duration
of the experiment. All mouse experiments were performed under protocols
approved by Institutional Committees on Animal Care at either the Massa-
chusetts Institute of Technology or Synta Pharmaceuticals.
Statistical Methods. All statistical analyses were performed using Prism 6.0
(GraphPad software). Statistical significance cutoff for all comparisons
was P < 0.05.
Accession Codes. Agilent microarray mRNA expression profiling data have
been deposited in the National Center for Biotechnology Information Gene
Expression Omnibus database, accession number GSE61906.
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